ArticlePeerJ2025
Correlation analysis of serum endothelial cell specific molecule-1, endothelial microparticles, hypoxia inducible factor-1α levels and acute myocardial infarction and their predictive value for major adverse cardiovascular events: a retrospective study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarker value of plasma endothelial microvesicle-derived circRNA 0006222 in vascular ageing and carotid atherosclerosis.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to analyse the correlation of endothelial cell specific molecule-1 (ESM-1), endothelial microparticles (EMPs) and hypoxia inducible factor-1α (HIF-1α) serum levels with the occurrence of acute myocardial infarction (AMI) and determine their short-term predictive value for major adverse cardiovascular events (MACE) following AMI treatment. Methods: Retrospective data analysis was performed on the medical records of 106 patients with AMI admitted to our hospital between October 2020 and October 2022. The control group consisted of 106 healthy volunteers that received a physical examination at our hospital's physical examination centre within the same time frame. ESM-1, EMP and HIF-1α serum levels were compared between the two groups. Independent risk variables for AMI were examined. Furthermore, these individuals were separated into the poor prognosis group ( Conclusion: Patients with AMI have abnormally high ESM-1, EMP and HIF-1α levels in their serum, all of which have been linked to the development of MACE. Together, these parameters have high sensitivity and specificity for early MACE identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.